Opportunity Analysis on the Global Continuous Glucose Monitoring (CGM) Systems/Devices Market to 2024 - Increasing Number of Patients Opting for Simplified CGM Devices

DUBLIN, Nov. 15, 2018 /PRNewswire/ --

The "Continuous Glucose Monitoring (CGM) Systems/Devices Market Size, Share & Trends Analysis Report By Component (Transmitters, Sensors, Insulin Pumps), By End Use (Hospitals, Homecare), And Segment Forecasts, 2018 - 2024" report has been added to ResearchAndMarkets.com's offering.

The global continuous glucose monitoring (CGM) devices market size is expected to reach USD 1.01 billion by 2024. The market is estimated to register a CAGR of 13.7% over the forecast period.

Growing cases of diabetes and introduction of novel and advanced diabetes care devices are the major factors driving the market growth.

These devices help manage diabetes while reducing individual insulin dosages. Integrated software within these devices provides users with insights about food consumption, medication, physical activity, and illnesses. Thus, an increasing number of diabetic patients are using these devices to manage and treat diabetes, which, in turn, is accelerating market growth.

With the advent of digital therapeutics, a rising number of CGM devices are being incorporated with apps and software to help patients with diabetes mellitus. Rise in the number of diabetes mellitus has been contributing toward market growth.

Key Findings

• Growing cases of diabetes is anticipated to propel market growth, with increasing number of patients opting for simplified CGM devices.
• CGM devices provide analysis of blood glucose levels from the tissue fluid at regular intervals of time, which is also driving their demand.
• Transmitters and receivers was the largest component type segment and is anticipated to maintain its dominance owing to their integral nature in these devices.
• Insulin pumps are anticipated to witness the highest CAGR during the forecast period due to their ability to maintain optimal blood glucose levels.
• Asia Pacific is the leading regional market, with Japan, China, and India on the forefront.
• North America led the global market in the past owing to wide usage of CGM devices as a result of higher number of target patients in the region.
• The European region followed the North American closely in terms of market revenue due to rise in the adoption of these devices in key countries such as U.K., Germany, France, Italy, and Spain.
• Some of the key companies present in the market are Pfizer Inc., Baxter International, Inc., Abbott Laboratories, Medtronic PLC, Animas Corporation, and Novo Nordisk A/S.

Key Topics Covered

Chapter 1. Methodology and Scope

1.1. Research methodology
1.2. Research scope & assumption
1.3. List of data sources

Chapter 2. Executive Summary
2.1. Continuous Glucose Monitoring Devices Market - Industry Summary and Key Buying Criteria, 2013 - 2024

Chapter 3. Continuous Glucose Monitoring Devices Industry Outlook
3.1. Market segmentation
3.2. Market size and growth prospects, 2013 - 2024
3.3. Continuous Glucose Monitoring Devices: Market dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing number of diabetes patients globally
3.3.1.2. Easy and efficient monitoring of current glucose values
3.3.2. Market restraint analysis
3.3.2.1. High surge in the price and cost of treatment
3.4. Continuous Glucose Monitoring Devices Market: Industry trend analysis
3.5. Continuous Glucose Monitoring Devices Market: PESTEL Analysis
3.6. Continuous Glucose Monitoring Devices Industry Analysis - Porter's Five Forces Model
3.7. Continuous Glucose Monitoring Devices: Company market share analysis (%), 2015
3.8. Key opportunities prioritized

Chapter 4. Continuous Glucose Marketing Product Outlook
4.1. Continuous Glucose Monitoring Revenue Share (%) Analysis, by Product, 2016 & 2024
4.2. Transmitters and Receivers
4.3. Sensors
4.4. Insulin Pumps

Chapter 5. Continuous Glucose Monitoring End-user Outlook
5.1. Continuous Glucose Monitoring Revenue Share (%) Analysis, by End-user, 2016 & 2024
5.2. Hospital
5.3. Homecare Diagnostics
5.4. Others

Chapter 6. Continuous Glucose Monitoring Regional Outlook
6.1. Continuous Glucose Monitoring Market Share (%) Analysis, by Region, 2014 & 2024
6.2. North America
6.3. Europe
6.4. Asia Pacific
6.5. MEA
6.6. Latin America

Chapter 7. Competitive Landscape
7.1. Roche Diagnostics
7.2. Dexcom Inc.
7.3. Abbott Laboratories
7.4. Medtronic Inc.
7.5. Animas Corporation
7.6. Novo Nordisk
7.7. Ypsomed AG
7.8. GlySens Incorporated

For more information about this report visit https://www.researchandmarkets.com/research/czcxgd/opportunity?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets